Epi-drug | Phase | Co-treatment | Number of patients | OR/CBR | Reference |
---|---|---|---|---|---|
Monotherapy | Â | Â | Â | Â | Â |
Azacitidine | I | None | 11 | 7/NA | [42] |
Azacitidine plus valproic acid | I | Â | 4 | 0/0 | [43] |
Decitabine | I | Â | 4 | 0/NA | [41] |
Fazarabine | I | Â | 3 | 1/1a | [44] |
 | II |  | 14 | 0/0 | [45] |
Phenylbutyrate | I | Â | 5 | 0/NA | [46] |
Vorinostat | II | Â | 14 | 0/3 | [47] |
 | II |  | 3 | 0/0 | [48] |
 | II |  | 26 | 1/1 | [49] |
 | Biomarker study |  | - | NA | [50] |
Vorinostat plus Decitabine | I | Â | 3 | 0/0 | [51] |
Total | Â | Â | 87 | 9 (10%)/NA | Â |
Combination therapies | Â | Â | Â | Â | Â |
Azacitidine | I | Erlotinib | 1 | 0/1 | [52] |
Decitabine | I | Carboplatin | 5 | 0/NA | [53] |
Entinostat | II | Exemestane | 64b | 4/18 | [54] |
Valproic acid | II | 5-Fluoruracil, epirubicin and cyclophosphamide | 15 | 9/NA | [55] |
 | I | Followed by epirubicine | 10 | 3/7 | [56] |
Valproic acid plus hydralazine | II | Standard chemotherapy | 3 | 0/0 | [57] |
 | I | Doxorubicin plus cyclophosphamide | 16 | 13/NA | [58] |
Vorinostat | I | Doxorubicin | 5 | 1/1 | [59] |
 | I-II | Paclitaxel plus bevacizumab | 54 | 26/42 | [60] |
 | II | Tamoxifen | 43 | 8/17 | [35] |
Total | Â | Â | 216 | 64 (30%)/NA | Â |